EGFR-targeted-dye conjugate

DRUG CLASS:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Head and Neck Cancer	No biomarker	Head and Neck Cancer	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3

Associations(2)